In a world where lip-service and corporate greenwashing are all too common, it’s refreshing to come across companies seemingly sincerely committed to making a difference. Especially in the psychedelic medicine space.
Journey Colab was founded in 2020 and is a mission-driven for-profit psychedelic pharmaceutical startup developing psychedelic treatments for addiction. Our conversation with co-founder and CEO Jeeshan Chowdhury gave us insight into a company not only working on an interesting and important indication (mescaline for addiction) but with a social stakeholder model firmly in mind.
“We’ve taken 10% of the founding equity of the company and placed that in an irrevocable trust, whereby irrevocable we mean that we can’t take the equity back for ant purpose. It’s for the purpose of serving the land and the people that the medicine comes from.”
“There is a huge need to responsibly steward these medicines into clinical practice, and we think that doing it in this stakeholder model gives us the governance and corporate structure to do that responsibly.”
See below for the full conversation and check out the Journey Colab website here
.
Interested in more executive interviews? See our chat with Field Trip Chairman Ronan Levy
